- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
PK/PD data, Retrospective data, Journal: Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV). (Pubmed Central) - Aug 24, 2024
P2
SARS-CoV-2 viral clearance kinetics in symptomatic, vaccinated individuals accelerated substantially over 2 years of the pandemic, necessitating a change to how new SARS-CoV-2 antivirals are compared (ie, shortening the period of pharmacodynamic assessment). As of writing (October, 2023), antiviral efficacy in COVID-19 can be efficiently assessed in vivo using serial qPCRs from duplicate oropharyngeal swab eluates taken daily for 5 days after drug administration.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
PK/PD data, Journal: Pharmacokinetic drug-drug interactions between Paxlovid (Pubmed Central) - Aug 24, 2024
As of writing (October, 2023), antiviral efficacy in COVID-19 can be efficiently assessed in vivo using serial qPCRs from duplicate oropharyngeal swab eluates taken daily for 5 days after drug administration. No abstract available
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Exploring early COVID-19 therapies, variants, and viral clearance dynamics: Insights from a high-risk outpatients study. (Pubmed Central) - Aug 22, 2024
In summary, the study did not find a significant association between specific early therapies and the time to achieve swab negativization. These findings underscore the complex dynamics of viral clearance and highlight the need for further research with larger patient cohorts to refine treatment protocols for high-risk COVID-19 patients.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Hepatosplenic Manifestations of Concomitant COVID-19 Infection and Severe Acute Babesiosis in a Healthy Adult Patient: Causality and Relationships (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_5363;
She was confirmed as acute severe babesia infection and required extended course with atovaquone, azithromycin & clindamycin...Even though ACE2 expression (potential entry target for SARS-COV-2) is low in blood vessels and medium in liver and spleen; high parasite load in conjunction with passage of RBCs through liver and spleen can be an effective medium for increased hemolysis along with toxicity to Paxlovid lowering the immune response...Further research is needed to evaluate if there is a casualty relationship between COVID-19 infection and acute severe hemolysis and hepatosplenic manifestations in babesiosis. Figure: CT imaging (left, upper right) of the patient showing significant hepatosplenomegaly without any other abnormalities, lower right shows microscopic evidence of intracellular inclusions (tetrads, ring forms etc. of babesia) in red blood cells in a peripheral blood smear of patient.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Acute Esophageal Necrosis in a COVID Positive Patient After Anti-Viral Therapy Complicated by Esophageal Stricture (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_2822;
He was discharged home on daily pantoprazole and famotidine and had a repeat EGD showing LA Grade D esophagitis without bleeding and benign-appearing esophageal stenosis (Figure 4)...Our patient being on tacrolimus, nirmatrelvir/ritonavir, and remdesivir highlights the need for further research on their potential for contributing to AEN...Image 4. Lower third of the esophagus, with LA Grade D esophagitis was found 35 cm from the incisors.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Recurrent Diverticulitis Associated With COVID-19 Infection (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_2492;
He was discharged on IV antibiotics for 2 weeks and transitioned to Apixaban...Clinicians are advised to be vigilant for the development of diverticulitis in patients with late GI symptoms after a COVID-19 infection and have a low threshold for abdominal imaging. Figure: CT abdomen-pelvis showing mid sigmoid giant diverticulum with hyper enhancing wall adhered to the adjacent wall of the urinary bladder and mild surrounding fat stranding supporting active inflammation.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study. (Pubmed Central) - Aug 14, 2024
The current study described the management of an older couple aged more than 85?years with these above-mentioned two diseases treated with 12?weeks of sofosbuvir/velpatasvir (Epclusa Molnupiravir and nirmatrelvir-ritonavir are moderately effective in reducing mortality risk among hospitalised oldest-old patients with COVID-19, regardless of their vaccination status.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD), Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
Journal: The safety of antivirals and neutralising monoclonal antibodies used in prehospital treatment of Covid-19. (Pubmed Central) - Aug 12, 2024
Sotrovimab, paxlovid and molnupiravir demonstrate acceptable safety profiles. Although the risk of AEs was greatest with sotrovimab, event rates were lower than comparative pre-pandemic period.
- |||||||||| Journal: Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients. (Pubmed Central) - Aug 10, 2024
We evaluated the susceptibility of SARS-CoV-2 against RNA-dependent RNA polymerase inhibitors (remdesivir and molnupiravir) and 3C-like protease inhibitors (nirmatrelvir and ensitrelvir), and that of influenza viruses against neuraminidase inhibitors (oseltamivir, peramivir, zanamivir, and laninamivir) and the cap-dependent endonuclease inhibitor baloxavir...The patients were treated with anti-influenza drugs and did not develop severe symptoms despite the co-infection. Since SARS-CoV-2 and influenza viruses continue to evolve, continuous monitoring of their circulation remains essential to assess public health measures and support clinical management.
- |||||||||| fluvoxamine / Generic mfg., Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: The global clinical studies of long COVID. (Pubmed Central) - Aug 10, 2024
Future studies should be designed to address sleep disorders which were seldomly included in registered clinical studies. Moreover, interventions aimed at treating the underlying pathophysiology of long COVID are also necessary but currently lacking.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Review, Journal: How I treat: Coronavirus disease 2019 in leukemic patients and hematopoietic cell transplant recipients. (Pubmed Central) - Aug 9, 2024
For cases of prolonged viral shedding, distinguishing between viable and non-viable viruses remains challenging but is crucial for determining contagiousness and guiding management decisions. Overall, individualized approaches considering immune status, clinical presentation, and viral kinetics are essential for effectively managing COVID-19 in leukemia patients.
- |||||||||| Trial completion date, Trial primary completion date: AGILE (Early Phase Platform Trial for COVID-19) (clinicaltrials.gov) - Aug 9, 2024
P1/2, N=600, Active, not recruiting,
Overall, individualized approaches considering immune status, clinical presentation, and viral kinetics are essential for effectively managing COVID-19 in leukemia patients. Trial completion date: Apr 2024 --> Jul 2025 | Trial primary completion date: Dec 2023 --> Jul 2025
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Retrospective data, Journal: Pediatric Nirmatrelvir/Ritonavir Prescribing Patterns During the COVID-19 Pandemic. (Pubmed Central) - Aug 3, 2024
However, nirmatrelvir/ritonavir prescribing to children with chronic conditions remains infrequent. Pediatric data concerning nirmatrelvir/ritonavir safety and effectiveness in preventing severe disease and hospitalization are critical optimizing clinical decision-making and use among children.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
NIRMATRELVIR/RITONAVIR-INDUCED SIADH: A CASE SERIES (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5298;
Nirmatrelvir/ritonavir-induced SIADH is an underappreciated cause of severe hyponatremia in the ICU. Clinicians should be aware of this rare complication as use of this important medication becomes more routine.
- |||||||||| Olumiant (baricitinib) / Eli Lilly, Paxlovid (nirmatrelvir/ritonavir) / Pfizer
SPONTANEOUS PNEUMOTHORAX: AN EMERGING COMPLICATION OF CORONAVIRUS DISEASE 19 (COVID-19) (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5112;
While the exact incidence of SP in COVID-19 patients remains to be fully elucidated, healthcare providers should maintain a high index of suspicion for this complication, particularly in patients with worsening respiratory status or refractory hypoxemia. Further research is needed to better understand the pathophysiology and risk factors predisposing COVID-19 patients to SP, which could inform targeted prevention and management strategies.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
PULMONARY EMBOLISM LEADING TO SYNCOPE WITH LARYNGEAL TRAUMA AND SUBCUTANEOUS EMPHYSEMA: AN UNCOMMON PRESENTATION OF A COMMON PROBLEM (Convention Center Exhibit Hall: Poster Area 4) - Jul 31, 2024 - Abstract #CHEST2024CHEST_3029;
Although rare, syncope can result in laryngeal trauma, which carries significant morbidity and mortality. Careful and thorough evaluation of the upper airway should be undertaken as part of any trauma evaluation; however, it is of particular importance in the setting of concomitant need for anticoagulation or thrombolytics, as in the setting of acute pulmonary embolism, such as this case.
- |||||||||| Cablivi (caplacizumab) / Sanofi
CAPLACIZUMAB: THE NEW KID ON THE BLOCK AGAINST VWF (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_2672;
She contracted COVID-19 two weeks prior and completed Paxlovid. Caplacizumab is a novel and effective treatment for acute TTP (including COVID-10-associated TTP) that can offer a plasma-free option for select patients.
- |||||||||| Ocrevus (ocrelizumab) / Roche
OCRELIZUMAB-INDUCED DIFFUSE CRYPTOGENIC ORGANIZING PNEUMONIA (Convention Center Exhibit Hall: Poster Area 3) - Jul 31, 2024 - Abstract #CHEST2024CHEST_1499;
Further research is needed to elucidate the mechanisms underlying such adverse events and to guide appropriate patient management strategies. Healthcare providers should remain vigilant for respiratory symptoms in patients receiving ocrelizumab and consider thorough pulmonary evaluation in cases of unexplained respiratory distress.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Nirmatrelvir for Adult Outpatients with Covid-19. Reply. (Pubmed Central) - Jul 31, 2024
Healthcare providers should remain vigilant for respiratory symptoms in patients receiving ocrelizumab and consider thorough pulmonary evaluation in cases of unexplained respiratory distress. No abstract available
- |||||||||| Evusheld (cilgavimab/tixagevimab) / AstraZeneca, Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
Journal: Saliva Is a Sensitive and Accessible Sample Both for SARS-CoV-2 Detection and for the Evaluation of Treatment Effectiveness in Follow-Up Studies. (Pubmed Central) - Jul 31, 2024
For this reason, in this study, we used, in parallel, saliva and NPS samples for the detection of SARS-CoV-2 by real-time RT-PCR in patients receiving Tixagevimab/Cilgavimab, Nirmatrelvir/Ritonavir, or Sotrovimab as a treatment against SARS-CoV-2. Our results showed a good correlation between the NPS and saliva samples for each drug; moreover, comparable changes in the cycle threshold (Ct) levels in saliva and NPSs were observed both 7 days and 30 days after treatment, thus confirming that the saliva represents a good matrix for in vivo follow-up studies verifying the effectiveness of treatments against SARS-CoV-2.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Nirmatrelvir-Ritonavir for Acute (Pubmed Central) - Jul 31, 2024
No abstract available Similarly, narrowly defined PASC occurred in 5,335 patients (20%) in the NMV-r cohort vs 6,271 patients (23.6%) in the non-NMV-r cohort between 30 and 90
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal, Real-world evidence, Real-world: Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 (Pubmed Central) - Jul 30, 2024
Similarly, narrowly defined PASC occurred in 5,335 patients (20%) in the NMV-r cohort vs 6,271 patients (23.6%) in the non-NMV-r cohort between 30 and 90 The application of Nirmatrelvir-ritonavir was associated with a significantly reduced risk of intubation or death in hospitalized COVID-19 patients who experienced symptoms for more than 5
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: The effect of oral antiviral therapy for COVID-19 in managing non-hospitalized patients with lung cancer. (Pubmed Central) - Jul 28, 2024
This study provides an updated progress in SARS-CoV-2 medications and a crucial guide for inventing novel interventions against COVID-19. The study suggests a favorable impact of oral antiviral therapy on the outcomes of COVID-19 in individuals with lung cancer and support the potential utility of oral antiviral agents in improving outcomes in this vulnerable population.
|
